Similarly, methylation-mediated silencing of GADD45A also contributes to prostate cancer resistance to docetaxel [57], indicating that both deacetylation and methylation of the GADD45A promoter region are involved in the transcriptional regulation of GADD45A. Moreover, it has been reported that the histone deacetylase inhibitor trichostatin A (TSA) could increase GADD45A expression to stimulate the cell cycle checkpoint and induce apoptosis, which provides a potential strategy for cancer treatment [58]. Here, GADD45A is linked to prostate carcinoma.